Aegis Life
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3040 Science Park Rd Ste 1100, San Diego...Phone Number
(858) 630-8005Website
aegis.lifeRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Aegis Life
Aegis Life, Inc. is a biotechnology company focused on preventing and treating infectious diseases through the development of nucleic acid-based vaccines and therapeutics using its proprietary Fusogenix Proteolipid Vehicle (PLV) delivery platform. Founded in 2020, the company is dedicated to addressing current and emerging contagions by leveraging over two decades of research in gene delivery. Aegis Life aims to rapidly prototype and manufacture vaccines and therapies, ensuring efficient delivery of genetic payloads to target cells. The company collaborates with various partners to enhance its GMP-manufacturing capacity, aiming to provide significant doses to those in need.Explore more
Aegis Life Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aegis Life your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Aegis Life
Click to see if Aegis Life had a recent Job posting/layoffs
Earning: See what the market has to say on Aegis Life recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Aegis Life has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aegis Life has new funding data
Check out if Aegis Life is spiking on competitors!
Aegis Life, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Aegis Life launches new products
Recommended Actions
Find VP level buyers at Aegis Life
Find more new buyers
Compare Similar Companies to Aegis Life
Compare insights from companies similar to Aegis Life, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aegis Life is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aegis Life is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aegis Life.
Aegis Life financials insights
Gather financial insights about Aegis Life, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$4.5M
Aegis Life Tech Stack
A closer look at the technologies used by Aegis Life
Most Recent Scoops
Project
Product Development, Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Partnership, Research & Development, Intellectual Property, Legal Affairs, Medical Research
Funding
Funding
Facilities Relocation / Expansion
Real Estate
Aegis Life News & Media
Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine Booster
EDMONTON, Alberta & SAN DIEGO--(BUSINESS WIRE)--Entos® Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix™ PLV™ nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced the first participant has been dosed in the phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002 as a COVID-19 booster vaccine. The phase 1/2 trial is sponsored by Entos and managed by Calian.Entos Pharmaceuticals Receives Approval from Health Canada to Begin Clinical Trial for COVID-19 Vaccine Booster
EDMONTON, Alberta & SAN DIEGO--(BUSINESS WIRE)--Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine. Formulated using the Entos FusoAegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform
SAN DIEGO & EDMONTON, Alberta--(BUSINESS WIRE)--Aegis Life, Inc. (Aegis) and its parent company Entos Pharmaceuticals (Entos) announced today that Aegis Life has received a program-related investment from the Bill & Melinda Gates Foundation (the “foundation”). Aegis will receive up to $4.45 million in funding through a convertible promissory note from the foundation’s Strategic Investment Fund for the purpose of developing DNA-based encoded neutralizing antibody therapies for infectious disAegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases
SAN DIEGO, Calif. & EDMONTON, Alberta--(BUSINESS WIRE)--Aegis Life, Inc. (Aegis), and its parent company Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix PLV delivery platform, today announced entering into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the Foundation will provide funding support to develop the Fusogenix PLV platform for the delivery of DNA-encoded monoclonal antibodi
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Aegis Life
Sign Up For FreeTo access detailed company insights
Aegis Life, Inc. is a biotechnology company focused on preventing and treating infectious diseases through the development of nucleic acid-based vaccines and therapeutics using its proprietary Fusogenix Proteolipid Vehicle (PLV) delivery platform. Founded in 2020, the company is dedicated to addressing current and emerging contagions by leveraging... Read More
